Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
暂无分享,去创建一个
S. Matsumoto | K. Yoh | K. Goto | G. Ishii | K. Tsuta | S. Oizumi | K. Nishi | N. Motoi | H. Itani | N. Furuya | A. Nakamura | S. Kuyama | N. Okamoto | K. Nishino | S. Miyamoto | I. Fukuda | Yuichiro Hayashi